Showing results (61-70 of 115) with videos related to
Sort By:
Pageof 12
Inflammatory Bowel Diseases|June 19, 2019
Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel DiseaseElena Ferrer-Picón, Isabella Dotti, Ana M Corraliza, et al.AIDS (London, England)|August 6, 2015
Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced diseaseMaria Casadellà, Christian Manzardo, Marc Noguera-Julian, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 5, 2013
Peak bone mass in young HIV-infected patients compared with healthy controlsEugènia Negredo, Pere Domingo, Elena Ferrer, et al.The Journal of Antimicrobial Chemotherapy|December 25, 2014
Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized studyMaria Saumoy, Jordi Ordóñez-Llanos, Esteban Martínez, et al.Sexually Transmitted Infections|May 11, 2022
Detecting anal human papillomavirus infection in men who have sex with men living with HIV: implications of assay variabilityMontserrat Torres, Ana Silva-Klug, Elena Ferrer, et al.The Journal of Antimicrobial Chemotherapy|January 23, 2015
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppressionMaria S Di Yacovo, José Moltó, Elena Ferrer, et al.International Journal of Cardiology|March 4, 2015
Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 scoreJosep Lupón, Hanna K Gaggin, Marta de Antonio, et al.Antiviral Therapy|May 12, 2004
Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapineMontserrat Plana, Elena Ferrer, Catalina Martínez, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 2, 2015
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)Jose M Miro, Christian Manzardo, Elena Ferrer, et al.European Heart Journal. Cardiovascular Imaging|January 21, 2024
Clinical and prognostic implications of left ventricular dilatation in heart failureGizem Kasa, Albert Teis, Gladys Juncà, et al.Pageof 12